Liquid Ventures I LP joins Cardiatec Biosciences as LQD Ventures exits
Published
Cardiatec Biosciences Ltd is a TechBio company based in Oakham that leverages artificial intelligence and multiomics data from human cardiac tissue to discover therapeutics for cardiovascular diseases. Founded in 2021, the company focuses on identifying new treatments by redesigning the drug discovery process.
The company's latest confirmation statement, filed in June 2026, indicates a shareholder change involving 3,262 Series Seed Preferred shares. Liquid Ventures I (GP) LLP, acting for Liquid Ventures I LP, has joined the cap table with this holding. This follows the exit of LQD Ventures LLP, which previously held the same number of shares. LQD Ventures LLP is also a shareholder in Aegiq Ltd.
Several institutional investors remain on the cap table. The Laidlaw Foundation continues to hold 34,155 shares, while Montage Ventures Fund III, LP retains 27,723 shares. Apex Digital Health EUVECA GmbH&Co KG holds 25,418 shares. Continuum Health Ventures maintains a significant presence through two separate entities, holding a combined total of 23,950 shares.
Other existing shareholders include Crista Galli Ventures Limited with 15,106 shares and Cambridge Technology Capital Limited with 11,250 shares. The register also features o2h Nominees Limited with 3,289 shares, the University of Cambridge with 2,467 shares, and the Francis Crick Institute Limited with 833 shares. Panacea Ventures Nominees I Ltd and Plug & Play EMEA Ventures GmbH both hold 1,042 shares.
Shareholder data
Source: Companies House confirmation statement (CS01) — period to , filed .
Changes in this confirmation statement
| Type | Shareholder | Shares | Change | Share classes |
|---|---|---|---|---|
| Exited | LQD VENTURES LLP | 3,262 | — | SERIES SEED PREFERRED 3,262 |
| New shareholder | LIQUID VENTURES I (GP) LLP AS GENERAL PARTNER FOR AND ON BEHALF OF LIQUID VENTURES I LP | 3,262 | — | SERIES SEED PREFERRED 3,262 |
Current shareholders (13)
| Shareholder | Total shares | Share classes |
|---|---|---|
| LAIDLAW FOUNDATION | 34,155 | PREFERENCE SHARES 16,447 SERIES SEED PREFERRED 17,708 |
| MONTAGE VENTURES FUND III, LP | 27,723 | SERIES SEED PREFERRED 27,723 |
| APEX DIGITAL HEALTH EUVECA GMBH&CO KG | 25,418 | PREFERENCE SHARES 16,447 SERIES SEED PREFERRED 8,971 |
| CONTINUUM HEALTH VENTURES ACTING FOR AND ON BEHALF OF CONTINUUM HEALTH VENTURES FUND I L.P. | 19,498 | SERIES SEED PREFERRED 19,498 |
| CRISTA GALLI VENTURES LIMITED | 15,106 | PREFERENCE SHARES 8,223 SERIES SEED PREFERRED 6,883 |
| CAMBRIDGE TECHNOLOGY CAPITAL LIMITED | 11,250 | SERIES SEED PREFERRED 11,250 |
| CONTINUUM HEALTH VENTURES ACTING FOR AND ON BEHALF OF CONTINUUM HEALTH VENTURES FUND I (CANADA) L.P. | 4,452 | SERIES SEED PREFERRED 4,452 |
| O2H NOMINEES LIMITED | 3,289 | ORDINARY 3,289 |
| LIQUID VENTURES I (GP) LLP AS GENERAL PARTNER FOR AND ON BEHALF OF LIQUID VENTURES I LP | 3,262 | SERIES SEED PREFERRED 3,262 |
| THE CHANCELLOR, MASTERS AND SCHOLARS OF THE UNIVERSITY OF CAMBRIDGE | 2,467 | PREFERENCE SHARES 2,467 |
| PANACEA VENTURES NOMINEES I LTD | 1,042 | SERIES SEED PREFERRED 1,042 |
| PLUG & PLAY EMEA VENTURES GMBH | 1,042 | SERIES SEED PREFERRED 1,042 |
| THE FRANCIS CRICK INSTITUTE LIMITED | 833 | SERIES SEED PREFERRED 833 |
Contact the editorial team at [email protected]